Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized twente trial: Comparison of 2-year clinical outcome

Catheterization and Cardiovascular Interventions

Volumn 85, Issue 1, 2015, Pages 74-81

  Sen, Hanim ^a   Lam, Ming Kai ^a   Tandjung, Kenneth ^a   Löwik, Marije M ^a   Stoel, Martin G ^a   De Man, Frits H A F ^a   Louwerenburg, J W ^a   Van Houwelingen, Gert K ^a   Linssen, Gerard C M ^b   Doggen, Carine J M ^c   Basalus, Mounir W Z ^a   Von Birgelen, Clemens ^a,c  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Drug eluting stent; Off label; Percutaneous coronary intervention; TWENTEtrial

Indexed keywords

EVEROLIMUS; ZOTAROLIMUS; CARDIOVASCULAR AGENT; RAPAMYCIN;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULANT THERAPY; ARTERIAL BYPASS GRAFT LESION; ARTICLE; BLOOD VESSEL OCCLUSION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY BIFURCATION LESION; DEVICE SAFETY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; HEART DEATH; HEART EJECTION FRACTION; HUMAN; IN-STENT RESTENOSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; THROMBUS; TRAGET VESSEL FAILURE; TREATMENT DURATION; UNPROTECTED LEFT MAIN LESION; VASCULAR DISEASE; VEIN GRAFT DISEASE; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; CORONARY DISEASE; DEVICES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NETHERLANDS; PROSTHESIS; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR AGENTS; CORONARY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NETHERLANDS; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923229711     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.25464     Document Type: Article

References (21)

1. Qasim A, Cosgrave J, Latib A, Colombo A. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications. Am J Cardiol 2007;100:1619-1624.
2. Beohar N, Davidson CJ, Kip KE, Goodreau L, Vlachos HA, Meyers SN, Benzuly KH, Flaherty JD, Ricciardi MJ, Bennett CL, Williams DO. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297:1992-2000.
3. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, Granada JF, Marulkar S, Nassif D, Cohen DJ, Kleiman NS, EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001-2009.
4. Brodie BR, Stuckey T, Downey W, Humphrey A, Bradshaw B, Metzger C, Hermiller J, Krainin F, Juk S, Cheek B, Duffy P, Smith H, Edmunds J, Varanasi J, Simonton CA, STENT (Strategic Transcatheter Evaluation of New Therapies) Group. Outcomes and complications with off-label use of drug-eluting stents: Results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. JACC Cardiovasc Interv 2008;1:405-414.
5. Harjai KJ, Orshaw P, Boura J, Sporn D. Comparison of long-term outcomes of bare metal or drug-eluting stent implantation in standard versus off-label coronary narrowings. Am J Cardiol 2009;103:1537-1545.
6. Jeremias A, Kirtane A. Balancing efficacy and safety of drug-eluting stents in patients undergoing percutaneous coronary intervention. Ann Intern Med 2008;148:234-238.
7. Latib A, Ferri L, Ielasi A, Godino C, Chieffo A, Magni V, Bassanelli G, Sharp AS, Gerber R, Michev I, Carlino M, Airoldi F, Sangiorgi GM, Montorfano M, Colombo A. Clinical outcomes after unrestricted implantation of everolimus-eluting stents. JACC Cardiovasc Interv 2009;2:1219-1226.
8. Galasso G, Piccolo R, Cassese S, Esposito G, Cirillo P, Leosco D, Rapacciuolo A, Sirico D, De Biase C, Niglio T, Piscione F. Unrestricted use of endeavor resolute zotarolimus-eluting stent in daily clinical practice: A prospective registry. J Invasive Cardiol 2012;24:251-255.
9. Romagnoli E, Godino C, Ielasi A, Gasparini G, Tzifos V, Sciahbasi A, Lioy E, Presbitero P, Colombo A, Sangiorgi G. Resolute Italian study in all comers: Immediate and one-year outcomes. Catheter Cardiovasc Interv 2012;79:567-574.
10. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-146.
11. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Said SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: The TWENTE trial. J Am Coll Cardiol 2012;59:1350-1361.
12. Stefanini GG, Serruys PW, Silber S, Khattab AA, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Di Mario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli AL, Gobbens P, Windecker S. The impact of patient and lesion complexity on clinical and angiographic outcomes after revascularization with zotarolimus- and everolimus-eluting stents: A substudy of the RESOLUTE All Comers Trial (a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol 2011;57:2221-2232.
13. Tandjung K, Sen H, Lam MK, Basalus MW, Louwerenburg JH, Stoel MG, van Houwelingen KG, de Man FH, Linssen GC, Said SA, Nienhuis MB, Löwik MM, Verhorst PM, van der Palen J, von Birgelen C. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. J Am Coll Cardiol 2013;61:2406-2416.
14. Vranckx P, Cutlip DE, Mehran R, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial infarction adjudication in contemporary all-comer stent trials: Balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. EuroIntervention 2010;5:871-874.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351.
16. Sen H, Lam MK, Tandjung K, Basalus MW, de Man FH, Louwerenburg HW, Stoel MG, van Houwelingen KG, Lowik MM, Linssen GC, Said SA, Nienhuis MB, Verhorst PM, van der Palen J, von Birgelen C. Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: Insights from 2-year outcome of the TWENTE trial. EuroIntervention, in press.
17. Silber S, Windecker S, Vranckx P, Serruys PW, RESOLUTE All Comers investigators. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011;377:1241-1247.
18. Mehilli J, Richardt G, Valgimigli M, Schulz S, Singh A, Abdel-Wahab M, Tiroch K, Pache J, Hausleiter J, Byrne RA, Ott I, Ibrahim T, Fusaro M, Seyfarth M, Laugwitz KL, Massberg S, Kastrati A. Zotarolimus- versus Everolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2013;62:2075-2082.
19. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes DJ, Waksman R, Mauri L, Meredith IT, Finn AV, Kim HS, Kubica J, Suryapranata H, Aprami TM, Di Pasquale G, von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: Comprehensive network meta-analysis. BMJ 2013;347:f6530.
20. Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR, Villadsen AB, Junker A, Hansen KN, Kaltoft A, Maeng M, Pedersen KE, Kristensen SD, Botker HE, Ravkilde J, Sanchez R, Aaroe J, Madsen M, Sorensen HT, Thuesen L, Lassen JF, Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) Investigators. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: The Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012;125:1246-1255.
21. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Juni P. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial. Lancet 2008;372:1163-1173.